Dataset opportunity
Sedivention — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Sedivention, usable for Diagnostic AI and Computer Vision.
Score
70
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Diagnostics Market was valued at USD 7.03 billion in 2025, projected to exhibit a CAGR of 46.06% from 2026-2034.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-12
„Unser Ziel ist es, kranken, übergewichtigen Menschen zu helfen“
devicemed.de ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
Focus on clinical validation and gastric nerve denervation research
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Sedivention holds a substantial Medical Imaging Dataset, comprising various image modalities supported by corresponding iot_data, medical_records, and regulatory documentation. This curated collection provides a rich, multi-faceted resource specifically structured for training and validating high-performance Diagnostic AI algorithms.
The value of this data is underscored by the booming AI in Diagnostics Market, which was valued at USD 7.03 billion in 2025 and is projected to grow at a CAGR of 46.06%. [2] While access is subject to strict regulatory frameworks like GDPR and negotiation due to sensitive patient information (PHI), the rarity and clinical depth of this dataset offer a significant competitive advantage for developers in this high-growth sector. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data involves sensitive patient health information (PHI); Data access subject to strict medical regulatory frameworks and GDPR; Ownership may be shared with clinical trial centers/hospitals · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Sedivention possesses a proprietary, multi-modal dataset from clinical studies validating its novel cryo-ablation weight loss technology. The dataset combines medical images, procedural sensor data, and unique metabolic research, offering a complete picture of the treatment's efficacy. For companies developing diagnostic AI, this is a rare opportunity to train and validate algorithms on a unique bariatric procedure, securing a first-mover advantage in a market projected to grow at over 46% annually.
See dimension details ↓- Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the rapid expansion of the AI in Diagnostics market, which is projected to grow at a CAGR of 46.06%. [2]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Sedivention is a pre-market MedTech SME developing a proprietary medical device and procedure for obesity treatment; the clinical data generated from their upcoming human trials is a high-value, niche, and dormant data asset. Issues: The company is in a pre-market, R&D phase and is currently preparing for its first-in-human study; the data asset (clinical trial data) does not exist yet but w; The prompt's description 'Medical Imaging Dataset Opportunity' is incorrect; the company's focus is on a cryo-ablation device for obesity, not imaging. [1, 5, 6
- Deep Qualification70
✓ pass — The target is a pre-market medical device company; the hypothesis of a 'substantial' existing dataset is contradicted by the company's own statements that clinical data is not yet available. While future clinical trials will generate valuable data, its existence is prospective, and ownership will likely be shared.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence consists of medical images from clinical studies that validate the safety and efficacy of a novel cryo-catheter, providing essential ground-truth data for training diagnostic AI models.
IoT / sensor data
The dataset includes time-series sensor data and temperature logs from the cryo-ablation procedure, which is critical for AI models that monitor procedural safety and predict treatment outcomes.
Regulatory records
This component contains proprietary text-based research and data detailing the procedure's effect on hunger hormones and metabolic markers, offering unique biological insights to enhance the predictive power of any AI model.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Sedivention Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics Market was valued at USD 7.03 billion in 2025, projected to exhibit a CAGR of 46.06% from 2026-2034 (source: Fortune Business Insights). Investment score 70.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Oportunidad de Conjunto de Datos de Imágenes Médicas — Bridgetolife
View opportunity →saludAdipogen — Oportunidad de Conjunto de Datos de Operaciones Industriales
View opportunity →atención médicaElevationspine — Oportunidad de Conjunto de Datos de Imágenes Médicas
View opportunity →Data Academy
Learn before you deal
- Su experiencia vale oro para la IA3 min read
- Sus videos de taller valen una fortuna3 min read
- Su idioma raro no se encuentra para la IA3 min read
News & Insights
Latest from the briefing
- Cómo los Derechos de Eliminación Masiva Afectan la Valoración de Conjuntos de Datos de Consumidores
- Valoración de Contenido con Derechos de Autor para Entrenamiento de IA: Un Marco de Valoración
- Estrategia de Datos Externos: Cuándo Comprar vs. Construir para el Entrenamiento de IA